1,25-二羟维生素D_3联合塞莱昔布对乳腺癌细胞株Hs578T生长及凋亡的影响  

The Effect of Combination Use of 1,25(OH)_2D_3 and Celecoxib on Growth and Apoptosis in Breast Cancer Cell Line Hs578T

作　　者：何雪琦[1] 鲍扬漪[1] 孙昕[1] 孟刚[1] 汪勤[1] 

机构地区：[1]安徽省合肥市第一人民医院肿瘤科,230061

出　　处：《医学研究杂志》2008年第8期66-68,共3页Journal of Medical Research

基　　金：合肥市科技局重点科研项目(合科2007第15号)

摘　　要：目的研究1,25-二羟维生素D31,25(OH)2D3联合塞莱昔布对乳腺癌细胞株Hs578T生长、细胞周期及凋亡的影响。方法采用四唑氮蓝比色(MTT)法检测细胞增生,流式细胞仪检测细胞周期及凋亡率。结果1,25(OH)2D3及塞莱昔布均可抑制乳腺癌细胞增生,诱导细胞凋亡,呈时间与剂量依赖性。当联合塞莱昔布时抑瘤率较1,25(OH)2D3单药具有叠加作用,但低于塞莱昔布单药。10-8mol/L联合塞莱昔布组抑瘤率高于10-7mol/L联合塞莱昔布组。结论1,25(OH)2D3及塞莱昔布可成为新一类乳腺癌预防、治疗药物。Objective To study the effect of combined 1,25 -dihydroxyvitamin D3 [1,25 （OH）2 D3] and celecoxib on growth, call cycle and apoptosis in breast cancer cell line Hs578T. Methods We compared cell numbers by using MTT method , analyzed cell cycle percentage and apoptosis with flow cytometric. Results Both with 1,25 （OH）2 D3 and celecoxib could inhibite tumor growth ,indue apoptosis in a dose-time -dependent manner, comparing with 1,25 （OH）2 D3 alone, combination wse of the two drugs had a additive effect but was inferior to cececoxib alone. The combination use of 10 μmol/L1,25 （OH）2D3 and celecoxib group is more effective than the combination use of 10^-7μmoL/L1,25 （OH） 2 D3 and celecoxib group. Conclusion 1,25 （ OH ）2D3 and celecoxib could be a new drug for the prevention and treatment of breast cancer.

关 键 词：1 25-二羟维生素D3 塞莱昔布 凋亡 细胞增生 

分 类 号：R977.24[医药卫生—药品] R737.9[医药卫生—药学]